Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 3-4/2014

01.02.2014 | originalarbeit

Österreichische 3e-Empfehlungen zu Diagnose und Management von Gicht 2013

verfasst von: MD Dr. Judith Sautner, MD, PhD Johann Gruber, MD, PhD Manfred Herold, MD, PhD Jochen Zwerina, MD, PhD Burkhard F. Leeb

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 3-4/2014

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Grundlagen

Gicht ist die häufigste entzündliche Gelenkerkrankung in der westlichen Welt und zeigt eine steigende Prävalenz. Nach dem Vorbild früherer 3e-Empfehlungen (Evidence-Expertise-Exchange) zu anderen rheumatologischen Problemen war das jetzige Ziel die Erstellung von internationalen Empfehlungen zur Diagnose und Therapie von Gicht und Hyperuricämie auf Basis einer systematischen Literatursuche.

Methodik

Zu Beginn des 3e-Projektes wurden in den teilnehmenden Ländern in einem Delphi-Prozess zunächst jeweils 10 nationale Fragen erstellt, die dann zu 10 internationalen Fragen verknüpft wurden. Danach wurde eine systematische Literatursuche durchgeführt. Auf Basis dieser Literatur wurden in einem nächsten Schritt wieder zunächst nationale und in weiterer Folge daraus internationale Empfehlungen formuliert. Der Grad der Zustimmung wurde dokumentiert und die Antworten nach Evidenzgrad klassifiziert.

Ergebnisse

Ein österreichisches Expertengremium erstellte unter Zuhilfenahme der verfügbaren Literatur 10 Empfehlungen zu Diagnostik und Therapie der Gicht bzw. Hyperuricämie.
Nach Publikation der internationalen 3e-Empfehlungen präsentieren wir hier einen Überblick über die nationalen österreichischen Fragen und Experten-Empfehlungen zu Diagnostik und Therapie der Gicht 2013 sowie einen Vergleich der österreichischen mit den internationalen Empfehlungen.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
1.
Zurück zum Zitat Li C, Hsieh MC, Chang SJ. Metabo lic syndrome, diabetes, and hyperuricemia. Curr Opin. Rheumatol. 2013 Mar;25(2):210–6. Li C, Hsieh MC, Chang SJ. Metabo lic syndrome, diabetes, and hyperuricemia. Curr Opin. Rheumatol. 2013 Mar;25(2):210–6.
3.
Zurück zum Zitat Kaya MG, Uyarel H, Akpek M, et al. Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012;109(4):486–91. PubMedCrossRef Kaya MG, Uyarel H, Akpek M, et al. Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012;109(4):486–91. PubMedCrossRef
4.
Zurück zum Zitat Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis.Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1301–11. PubMedCentralPubMedCrossRef Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis.Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1301–11. PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part II: Management.Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312–24. PubMedCentralPubMedCrossRef Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part II: Management.Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312–24. PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 ACR guidelines for management of gout. Part I: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012 Oct;64(19):1431–46. CrossRef Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 ACR guidelines for management of gout. Part I: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012 Oct;64(19):1431–46. CrossRef
7.
Zurück zum Zitat Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 ACR guidelines for management of gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2021 Oct;64(19):1447–61. CrossRef Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 ACR guidelines for management of gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2021 Oct;64(19):1447–61. CrossRef
8.
Zurück zum Zitat Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2013, 10.1136/annrheumdis-2013–203325. Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2013, 10.1136/annrheumdis-2013–203325.
9.
Zurück zum Zitat Janssens HJ, Janssen M, van den Lisdonk EH, et al. Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care. Ann Rheum Dis. 2010;69:1255–6. PubMedCrossRef Janssens HJ, Janssen M, van den Lisdonk EH, et al. Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care. Ann Rheum Dis. 2010;69:1255–6. PubMedCrossRef
10.
Zurück zum Zitat Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol. 2009;15:22–4. PubMedCrossRef Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol. 2009;15:22–4. PubMedCrossRef
11.
Zurück zum Zitat Glazebrook KN, Guimaraes LS, Murthy NS, et al. Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. Radiology. 2011;261:516–24. PubMedCrossRef Glazebrook KN, Guimaraes LS, Murthy NS, et al. Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. Radiology. 2011;261:516–24. PubMedCrossRef
12.
Zurück zum Zitat Lai KL, Chiu YM. Role of ultrasonography in diagnosing gouty arthritis. J Med Ultrasound. 2011;19:7–13. CrossRef Lai KL, Chiu YM. Role of ultrasonography in diagnosing gouty arthritis. J Med Ultrasound. 2011;19:7–13. CrossRef
13.
Zurück zum Zitat Bhole V, Choi JW, Kim SW, et al. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am J Med. 2010 Oct;123(10):957–61. PubMedCentralPubMedCrossRef Bhole V, Choi JW, Kim SW, et al. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am J Med. 2010 Oct;123(10):957–61. PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Hozawa A, Folsom AR, Ibrahim H, et al. Serum uric acid and risk of ischemic stroke: the ARIC Study. Atherosclerosis. 2006 Aug;187(2):401–7. PubMedCrossRef Hozawa A, Folsom AR, Ibrahim H, et al. Serum uric acid and risk of ischemic stroke: the ARIC Study. Atherosclerosis. 2006 Aug;187(2):401–7. PubMedCrossRef
15.
Zurück zum Zitat Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006 Jun;37(6):1503–7. PubMedCrossRef Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006 Jun;37(6):1503–7. PubMedCrossRef
16.
Zurück zum Zitat Kuo CF, See LC, Luo SF, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology. 2010 Jan;49(1):141–6. PubMedCrossRef Kuo CF, See LC, Luo SF, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology. 2010 Jan;49(1):141–6. PubMedCrossRef
17.
Zurück zum Zitat Kuo CF, See LC, Yu KH, et al. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology. 2013 Jan;52(1):127–34. PubMedCrossRef Kuo CF, See LC, Yu KH, et al. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology. 2013 Jan;52(1):127–34. PubMedCrossRef
18.
Zurück zum Zitat Strasak AM, Rapp K, Hilbe W, et al. VHM & PP Study Group. The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28000 older Austrian women. Ann Oncol. 2007 Nov;18(11):1893–7. PubMedCrossRef Strasak AM, Rapp K, Hilbe W, et al. VHM & PP Study Group. The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28000 older Austrian women. Ann Oncol. 2007 Nov;18(11):1893–7. PubMedCrossRef
19.
Zurück zum Zitat Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009 Feb;169(4):342–50. PubMedCentralPubMedCrossRef Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009 Feb;169(4):342–50. PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Janssens HJ, Jannse M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371:1854–60. PubMedCrossRef Janssens HJ, Jannse M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371:1854–60. PubMedCrossRef
21.
Zurück zum Zitat Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: 24h outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060–8. PubMedCrossRef Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: 24h outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060–8. PubMedCrossRef
22.
Zurück zum Zitat Willburger RE, Mysler E, Derbot J, et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology. 2007;46(7):1126–32. PubMedCrossRef Willburger RE, Mysler E, Derbot J, et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology. 2007;46(7):1126–32. PubMedCrossRef
23.
Zurück zum Zitat Choi HK, Atkinson K, Karlson E, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350:1093–103 PubMedCrossRef Choi HK, Atkinson K, Karlson E, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350:1093–103 PubMedCrossRef
24.
25.
Zurück zum Zitat Dalbeth N, Wong S, Gamble GD, et al. Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Ann Rheum Dis. 2010 69(9):1677–82. Dalbeth N, Wong S, Gamble GD, et al. Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Ann Rheum Dis. 2010 69(9):1677–82.
26.
Zurück zum Zitat Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficay and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):63. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficay and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):63.
27.
Zurück zum Zitat Singh JA;Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis. 2008 Sep;67(9):1310–6. PubMedCrossRef Singh JA;Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis. 2008 Sep;67(9):1310–6. PubMedCrossRef
28.
Zurück zum Zitat Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31(12):2429–32. PubMed Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31(12):2429–32. PubMed
29.
Zurück zum Zitat Paulus HE, Schlosstein LH Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout. A placebo controlled study od probenecid-treated pateints. Arthritis Rheum. 1974;17(5):609–14. PubMedCrossRef Paulus HE, Schlosstein LH Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout. A placebo controlled study od probenecid-treated pateints. Arthritis Rheum. 1974;17(5):609–14. PubMedCrossRef
30.
Zurück zum Zitat Schlesinger N, Mysler E, Lin HY, et al. Cnakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70(7):1264–71. PubMedCentralPubMedCrossRef Schlesinger N, Mysler E, Lin HY, et al. Cnakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70(7):1264–71. PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Karimzadeh H, Nazari J, Mottaghi P, Kabiri P. Different duration of colchicine for preventing recurrence of gouty arthritis. J Res Med Sci. 2006;11(2):104–7. Karimzadeh H, Nazari J, Mottaghi P, Kabiri P. Different duration of colchicine for preventing recurrence of gouty arthritis. J Res Med Sci. 2006;11(2):104–7.
32.
Zurück zum Zitat Stamp LK, O’Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63(2):412–21. PubMedCrossRef Stamp LK, O’Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63(2):412–21. PubMedCrossRef
33.
Zurück zum Zitat Ohue T, Yamamoto T, et al. Effects of allopurinol and benzbromarone on renal clearance of creatinine and uric acid in gouty patients. Japanese J Rheumatology. 1991;3(1):21–7. Ohue T, Yamamoto T, et al. Effects of allopurinol and benzbromarone on renal clearance of creatinine and uric acid in gouty patients. Japanese J Rheumatology. 1991;3(1):21–7.
34.
Zurück zum Zitat De Angelis S, Noce A, Di Renzo L, et al. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind- randomized study. Eur Rev Med Pharmacol Sci. 2007;11:179–84. De Angelis S, Noce A, Di Renzo L, et al. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind- randomized study. Eur Rev Med Pharmacol Sci. 2007;11:179–84.
35.
Zurück zum Zitat Jordan KM, Cameron S, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout on behalf of the British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). Rheumatology. 2007;26:1372–74. CrossRef Jordan KM, Cameron S, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout on behalf of the British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). Rheumatology. 2007;26:1372–74. CrossRef
36.
Zurück zum Zitat Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum. 2006;55(5):786–90. PubMedCrossRef Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum. 2006;55(5):786–90. PubMedCrossRef
37.
Zurück zum Zitat Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321–25. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321–25.
38.
Zurück zum Zitat Dalbeth N, McQueen FM, Singh JA, et al. Tophus measurement as an outcome measure for clinical trials of chronic gout: Progress and research priorities. J Rheumatol. 2011;38(7):1458–61. PubMedCrossRef Dalbeth N, McQueen FM, Singh JA, et al. Tophus measurement as an outcome measure for clinical trials of chronic gout: Progress and research priorities. J Rheumatol. 2011;38(7):1458–61. PubMedCrossRef
39.
Zurück zum Zitat Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol. 2007;34(9):1888–93. PubMed Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol. 2007;34(9):1888–93. PubMed
40.
Zurück zum Zitat Khanna PP, Perez-Ruiz F, Maranian P, Khanna D. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology. 2011;50(4):740–45. PubMedCentralPubMedCrossRef Khanna PP, Perez-Ruiz F, Maranian P, Khanna D. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology. 2011;50(4):740–45. PubMedCentralPubMedCrossRef
41.
Zurück zum Zitat Taylor WJ, Colvine K, Gregory K, et al. The Health Assessment Questionnaire Disability Index is a valid measure of physical function in gout. Clin Exp Rheumatol. 2008;26(4):620–26. PubMed Taylor WJ, Colvine K, Gregory K, et al. The Health Assessment Questionnaire Disability Index is a valid measure of physical function in gout. Clin Exp Rheumatol. 2008;26(4):620–26. PubMed
42.
Zurück zum Zitat Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase fort he treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711–20. PubMedCrossRef Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase fort he treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711–20. PubMedCrossRef
43.
Zurück zum Zitat Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273–82. PubMedCrossRef Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273–82. PubMedCrossRef
44.
Zurück zum Zitat Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophy in chronic gout. Arthritis Rheum. 2002;47(4):356–60. PubMedCrossRef Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophy in chronic gout. Arthritis Rheum. 2002;47(4):356–60. PubMedCrossRef
45.
Zurück zum Zitat Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987 Mar;82(3):421–6. PubMedCrossRef Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987 Mar;82(3):421–6. PubMedCrossRef
46.
Zurück zum Zitat Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011;6(8):1887–94. PubMedCentralPubMedCrossRef Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011;6(8):1887–94. PubMedCentralPubMedCrossRef
47.
Zurück zum Zitat Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39(4):1227–33. PubMedCrossRef Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39(4):1227–33. PubMedCrossRef
48.
Zurück zum Zitat Siu YP, Leung KT, Tong MK and Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006 Jan:47(1):51–9. PubMedCrossRef Siu YP, Leung KT, Tong MK and Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006 Jan:47(1):51–9. PubMedCrossRef
49.
Zurück zum Zitat Perez-Ruiz F, Carmona L, Yebenes MJ, et al. An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study. J Clin Rheumatol. 2011;17:349–55. PubMedCrossRef Perez-Ruiz F, Carmona L, Yebenes MJ, et al. An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study. J Clin Rheumatol. 2011;17:349–55. PubMedCrossRef
50.
Zurück zum Zitat Haindl PM, Rintelen B, Brezinschek HP, et al. Österreichische Empfehlungen zum Gebrauch von Methotrexat in der Rheumatologie – Expertenkonsensus basierend auf einer systematischen Literatursuche. Akt Rheumatol. 2010;35:251–9. CrossRef Haindl PM, Rintelen B, Brezinschek HP, et al. Österreichische Empfehlungen zum Gebrauch von Methotrexat in der Rheumatologie – Expertenkonsensus basierend auf einer systematischen Literatursuche. Akt Rheumatol. 2010;35:251–9. CrossRef
Metadaten
Titel
Österreichische 3e-Empfehlungen zu Diagnose und Management von Gicht 2013
verfasst von
MD Dr. Judith Sautner
MD, PhD Johann Gruber
MD, PhD Manfred Herold
MD, PhD Jochen Zwerina
MD, PhD Burkhard F. Leeb
Publikationsdatum
01.02.2014
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 3-4/2014
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-013-0469-1